Loading search results

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Formulated product

Pioglitazone Mylan 15 mg compresse

The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.

TABLET

View registry record

Eligibility Criteria

Sexall

Age GroupsAdult (18-64)

You may not qualify if:

i. Unable to consent (adults lacking capacity); ii. Participants that have a diagnosis of other types of vitiligo including segmental and mixed vitiligo; iii. Has ≥50% leukotrichia on face or body; iv. Unable to return for follow-up visits; v. Pregnant women and/or breastfeeding, or those who have recently delivered a baby within the past 6 months; vi. Has any other dermatological diseases that would interfere with vitiligo assessments; vii. History of type I or II diabetes viii. Has a transplanted organ, which requires continued immunosuppression; ix. Has a history of any oncological malignancy; x. Familiar atypical multiple mole and melanoma (FAMMM) syndrome; xi. Systemic lupus erythematosus; xii. Dermatomyositis; xiii. Genetic conditions that predispose an individual to skin cancer (Gorlin syndrome, xeroderma pigmentosum); xiv. Bloom syndrome or Cockayne syndrome; xv. Has had major surgery within 3 months before Screening OR has a major surgery planned during the study; xvi. Has hypersensitivity to the active substance or to any of the excipients; xvii. Has cardiac failure or history of cardiac failure (NYHA stages I to IV); xviii. Has current bladder cancer or a history of bladder cancer xix. Has uninvestigated macroscopic haematuria. xx. Any evidence of fluid overload xxi. Prior/Concurrent investigational clinical study experience; xxii. Enrolled in a clinical study of any other investigational drug or device; xxiii. Liver disease, or kidney disease; xxiv. Hypoglycemia as defined by fasting blood glucose <70 mg/dL assessed at a fasting study visit; xxv. ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary: xxvi. Absolute neutrophil count of <2.5 x 109/L (<2500/mm3); xxvii. Hemoglobin <10.0 g/dL or hematocrit <30%; xxviii. Platelet count below the lower limit of normal (LLN) at Screening; xxix. Absolute lymphocyte count of <0.8 x 109 /L (<800/mm3); xxx. Serum creatinine > upper limit of normal (ULN) or eGFR <60 ml/min/1.73m2 based on the age-appropriate calculation. xxxi. Enzymes aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values >2 times the ULN; xxxii. Total bilirubin 1.5 times the ULN; subjects with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ULN; xxxiii. Creatine kinase (CK) >3 times the ULN and positive urine myoglobin; xxxiv. In the opinion of the investigator, have any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject’s participation in the study. xxxv. Patients who, in the opinion of the investigator, are unable or unlikely to comply with the administration schedule and study evaluation.

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier

2025-523266-24-00

Data provider

European Medicines Agency (EMA)

Normalization version

ctis-v1

Source retrieved: 2026-10-30 06:33:24 UTC

“A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo”

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may not qualify if:

Sponsors & Collaborators

Study Sites (2)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may not qualify if:

Sponsors & Collaborators

Study Sites (2)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

Locations